27
Views
12
CrossRef citations to date
0
Altmetric
Antimicrobial Chemotherapy

Antimicrobial Resistance of Respiratory Pathogens in North African Countries

Pages 627-632 | Published online: 18 Jul 2013
 

Abstract

This study reports the antimicrobial resistance of Streptococcus pneumoniae, Haemophilus influenzae and Streptococcus pyogenes isolated from patients in Algeria, Morocco and Tunisia. 672 non-duplicate isolates were recovered from may 2006 to may 2007. The minimum inhibitory concentrations (MICs) were determined using the e-test and interpreted according to EUCAST guidelines. Among 236 S. pneumoniae, 47% were penicillin non-susceptible (PNSP) with 3% of strains being highly resistant; 20.4% and 17.4% had decreased susceptibility to amoxicillin and cefotaxime, respectively. Dual resistance to penicillin and erythromycin was observed in 30.1%. All isolates were susceptible to levofloxacin except one. Among 262 H. influenzae, 13.3% were amoxicillin-resistant and beta-lactamase producers. Two isolates were beta-lactamase-positive and amoxicillin-clavulanate-resistant. All isolates were susceptible to cefixime, cefotaxime and levofloxacin. All S. pyogenes (174) were susceptible to betalactams with 5.7% resistant to erythromycin. Five had decreased susceptibility to levofloxacin. These data on respiratory tract pathogens indicate the high prevalence of PNSP in North African countries.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.